The global mucous membrane pemphigoid treatment market size is expected to be valued at US$ 5.1 Billion in 2022. It is set to reach US$ 8.4 Billion in 2032 and exhibit growth at a steady CAGR of 5.9% in the forecast period from 2022 to 2032. The high demand for immunosuppressants for the treatment of mucous membrane pemphigoid is anticipated to fuel the market in the near future.
| Report Attribute | Details |
| Mucous Membrane Pemphigoid Treatment Market Estimated Base Year Value (2021) | US$ 4.3 Billion |
| Mucous Membrane Pemphigoid Treatment Market Expected Market Value (2022) | US$ 5.1 Billion |
| Mucous Membrane Pemphigoid Treatment Market Anticipated Forecast Value (2032) | US$ 8.4 Billion |
| Mucous Membrane Pemphigoid Treatment Market Projected Growth Rate (2022-2032) | 5.9% CAGR |
Mucous membrane pemphigoid is referred to as a group of rare chronic autoimmune disorders. These are characterized by blistering lesions that affect the mucous membranes of an individual’s body.
Mucous membranes of the eyes, mouth, genitalia, nose, anus, and throat are often affected. The first sign of this condition is usually a blistered and red mouth. The inner cheek, roof of the mouth, and gums can also be affected.
It occurs when an individual’s natural defenses of the body against invading or foreign organisms start attacking healthy tissue for no underlying causes. This condition affects females more than males across the globe.
Healthcare professionals usually examine the sample of tissue under a microscope to detect mucous membrane pemphigoid by its appearance. Sometimes, they utilize certain special chemical stains to see antibody deposits under the microscope.
The rising awareness programs conducted by regulatory bodies to educate the masses about the availability of advanced treatment options is expected to augur well for the mucous membrane pemphigoid treatment market growth. The high demand for better-quality healthcare products, especially in developing countries is another factor that is likely to propel the market.
The increasing preference for oral medications among patients is set to compel several pharmaceutical companies to develop new drugs. The rising geriatric population worldwide is also likely to bode well for the global market.
The lack of funding by governments of developing countries to conduct research activities to come up with new drugs may obstruct the global mucous membrane pemphigoid treatment market size in the assessment period. Apart from that, the expensive nature of latest treatment options can hamper the growth as people in these countries cannot usually afford them.
The rising prevalence of various autoimmune diseases in Canada and the U.S. is expected to spur the North America mucous membrane pemphigoid treatment market share in the evaluation period. According to the National Institute of Environmental Health Sciences, autoimmune diseases affect more than 24 million people in the U.S. alone. This number is set to grow in the future years, thereby augmenting the market.
The increasing usage of novel drugs by clinicians that are made using a combination of nicotinamide and doxycycline is another crucial factor that is projected to accelerate the market. Corticosteroids are also set to be provided to patients either through injections or direct application on the affected area.
Latin America is estimated to remain in the second position owing to the rapid development of advanced healthcare infrastructure in Mexico, Argentina, and Brazil. The presence of a large patient pool in these countries is also expected to push the demand for mucous membrane pemphigoid treatment options in Latin America.
The increasing usage of high doses of prednisone along with numerous immunosuppressants, such as cyclophosphamide, rituximab, mycophenolate mofetil, and azathioprine in this region is likely to fuel the growth. The rising focus of manufacturers on new product launches and approvals is also projected to bode well for the regional market.
Some of the key players operating in the global mucous membrane pemphigoid treatment market are Astellas Pharma US, Inc., Genentech, Inc., Actavis Plc., Merck Sharp & Dohme, EPI Health, LLC., Sun Pharma Company, Pfizer Inc., GlaxoSmithKline plc., Lipidor AB, and Bausch Health among others.
Leading players are increasingly focusing on investing huge sums in research and development activities to introduce innovative treatment options. Some of the other players are aiming to strengthen their positions by engaging in partnerships with local or international companies. Meanwhile, a few other firms are joining hands with government bodies to conduct awareness programs and initiate healthcare campaigns for people. These vital strategies are anticipated to help major players in surging the sales of mucous membrane pemphigoid treatment drugs.
| Report Attribute | Details |
| Growth Rate | CAGR of 5.9% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2015-2020 |
| Forecast Period | 2022-2032 |
| Quantitative Units | Revenue in USD Billion, Volume in Kilotons and CAGR from 2022-2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
By Drug Class:
By Route of Administration:
By Distribution Channel:
By Region:
The global mucous membrane pemphigoid treatment market is anticipated to surpass US$ 8.4 Billion by 2032.
North America is likely to lead the mucous membrane pemphigoid treatment market.
Astellas Pharma US, Inc., Genentech, Inc., Actavis Plc., Merck Sharp & Dohme, EPI Health, LLC., Sun Pharma Company, and Pfizer Inc. are some of the key players in the mucous membrane pemphigoid treatment market.
Explore Similar Insights
Mucous Membrane Pemphigoid Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
